Efficacy and Safety of Pharmacological Treatments in Borderline Personality Disorder: A Systematic Review and Network Meta-Analysis

Why It Matters

Understanding which medications provide genuine clinical benefit helps clinicians avoid unnecessary polypharmacy and informs guideline updates for a disorder with high morbidity and treatment dropout.

Key Takeaways

• No drug demonstrates clear superiority across all BPD symptoms
• Atypical antipsychotics modestly reduce aggression
• Lamotrigine improves affective instability with tolerable side effects
• Combination with psychotherapy yields better outcomes
• High dropout rates limit pharmacotherapy evidence

Pulse Analysis

Borderline personality disorder remains a therapeutic challenge, with psychotherapy regarded as first‑line but many patients requiring adjunctive medication to manage impulsivity, aggression, and mood swings. The new network meta‑analysis aggregates over two dozen randomized trials, applying rigorous Bayesian methods to rank drugs by efficacy and safety. By directly comparing agents that have never been juxtaposed in head‑to‑head trials, the study offers a clearer hierarchy of pharmacologic options than traditional pairwise meta‑analyses.

The findings reveal that atypical antipsychotics, particularly olanzapine and aripiprazole, provide modest reductions in aggression and irritability, yet their metabolic side‑effects and higher discontinuation rates temper enthusiasm. Lamotrigine emerges as the most favorable mood stabilizer, showing consistent improvement in affective instability with a relatively benign safety profile. In contrast, SSRIs, carbamazepine, and topiramate failed to demonstrate statistically significant benefits over placebo, and several agents were associated with increased dropout, underscoring the difficulty of maintaining adherence in this population.

For clinicians, the analysis suggests a pragmatic approach: prioritize lamotrigine for affective symptoms, consider low‑dose atypical antipsychotics for severe aggression, and always pair medication with evidence‑based psychotherapies such as dialectical behavior therapy. The study also highlights gaps—most trials are short‑term, underpowered, and lack diverse patient samples—calling for larger, longer‑duration investigations. As the pharmaceutical landscape evolves, these insights can shape prescribing guidelines, insurance coverage decisions, and future research funding aimed at improving outcomes for individuals living with BPD.